Comparing the current results to its competitors, Spyre Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.66 %, recorded in the same quarter.
Spyre Therapeutics Inc 's Comment on Competition and Industry Peers
The company anticipates significant competition from biopharmaceutical firms developing treatments for inflammatory diseases such as moderate-to-severe inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and psoriatic arthritis (PsA). Competitors include manufacturers of TNF antibodies like Humira (AbbVie), Remicade and Simponi (Johnson & Johnson), Cimzia (UCB), and Enbrel (Amgen); IL-12/23 and IL-23 antibodies including Stelara and Tremfya (Johnson & Johnson), Skyrizi (AbbVie), Omvoh (Lilly), and tildrakizumab (Sun Pharma); the α4ß7 antibody Entyvio (Takeda); JAK inhibitors such as Xeljanz (Pfizer), Rinvoq (AbbVie), and Olumiant (Lilly); S1P1 receptor modulators including Zeposia (Bristol Myers Squibb) and Velsipity (Pfizer); the T-cell activation inhibitor Orencia (Bristol Myers Squibb); IL-6R antibodies Actemra (Roche) and Kevzara (Sanofi); the CD20 antibody Rituxan (Roche); the IL-1R antibody Kineret (Sobi); the PDE4 antibody Otezla (Amgen); and other novel agents under development by companies including Merck, Roche/Roivant, Sanofi/Teva, Innovent, Lilly, Gilead, Palisade Bio, Pfizer, Simcere, Boehringer Ingelheim, Xencor, Anaptys, Zenas, Sonoma Biotherapeutics, MoonLake, and Sun Pharma. Additionally, the company’s products may face competition from approved or developing biosimilars and generics.
Atea Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing antiviral therapeutics to combat infectious diseases. Their business model revolves around identifying and advancing novel drug candidates that target specific viral mechanisms and inhibit their replication. This includes conducting preclinical and clinical trials, engaging in strategic partnerships, and ultimately bringing effective antiviral treatments to market.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
Cadrenal Therapeutics Inc's business model revolves around the development and commercialization of innovative therapies in the field of renal diseases.
Sources:
Spyre Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Spyre Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
